array:21 [
  "pii" => "X2013251414053654"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2013.Oct.12256"
  "estado" => "S300"
  "fechaPublicacion" => "2014-01-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia (English Version). 2014;34:46-52"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 6260
    "formatos" => array:3 [
      "EPUB" => 336
      "HTML" => 5109
      "PDF" => 815
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699514053657"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2013.Oct.12256"
      "estado" => "S300"
      "fechaPublicacion" => "2014-01-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2014;34:46-52"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 12049
        "formatos" => array:3 [
          "EPUB" => 339
          "HTML" => 10822
          "PDF" => 888
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "Valor diagnóstico de los niveles séricos del receptor soluble de la uroquinasa en adultos con síndrome nefrótico idiopático"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "46"
            "paginaFinal" => "52"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig1"
            "etiqueta" => "Tab.  2"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier España"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "12256_19904_50074_es_12256_t2.jpg"
                "Alto" => 107
                "Ancho" => 600
                "Tamanyo" => 55813
              ]
            ]
            "descripcion" => array:1 [
              "es" => "Variables asociadas a niveles circulantes de receptor soluble de la uroquinasa. ANOVA"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Alfons Segarra, Elías Jatem, M. Teresa Quiles, M. Antonia Arbós, Elena Ostos, Helena Ostos, Naiara Valtierra, Clara Carnicer, Irene Agraz, M. Teresa Salcedo"
            "autores" => array:10 [
              0 => array:2 [
                "nombre" => "Alfons"
                "apellidos" => "Segarra"
              ]
              1 => array:2 [
                "nombre" => "Elías"
                "apellidos" => "Jatem"
              ]
              2 => array:2 [
                "nombre" => "M. Teresa"
                "apellidos" => "Quiles"
              ]
              3 => array:2 [
                "nombre" => "M. Antonia"
                "apellidos" => "Arbós"
              ]
              4 => array:2 [
                "nombre" => "Elena"
                "apellidos" => "Ostos"
              ]
              5 => array:2 [
                "nombre" => "Helena"
                "apellidos" => "Ostos"
              ]
              6 => array:2 [
                "nombre" => "Naiara"
                "apellidos" => "Valtierra"
              ]
              7 => array:2 [
                "nombre" => "Clara"
                "apellidos" => "Carnicer"
              ]
              8 => array:2 [
                "nombre" => "Irene"
                "apellidos" => "Agraz"
              ]
              9 => array:2 [
                "nombre" => "M. Teresa"
                "apellidos" => "Salcedo"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251414053654"
          "doi" => "10.3265/Nefrologia.pre2013.Oct.12256"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414053654?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514053657?idApp=UINPBA000064"
      "url" => "/02116995/0000003400000001/v0_201502091353/X0211699514053657/v0_201502091353/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251414053662"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2013.Oct.12272"
    "estado" => "S300"
    "fechaPublicacion" => "2014-01-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2014;34:53-61"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5868
      "formatos" => array:3 [
        "EPUB" => 287
        "HTML" => 4826
        "PDF" => 755
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "53"
          "paginaFinal" => "61"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Valor de los niveles séricos del receptor soluble de la uroquinasa en el diagnóstico diferencial entre glomeruloesclerosis focal y segmentaria idiopática y secundaria"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "12272_16025_54379_en_t112272i.jpg"
              "Alto" => 1265
              "Ancho" => 2168
              "Tamanyo" => 479310
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Clinical-demographic variables according to patient groups"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Alfons Segarra, Elías Jatem, M. Teresa Quiles, M. Antonia Arbós, Elena Ostos, Helena Ostos, Naiara Valtierra, Clara Carnicer, M. Teresa Salcedo"
          "autores" => array:9 [
            0 => array:2 [
              "nombre" => "Alfons"
              "apellidos" => "Segarra"
            ]
            1 => array:2 [
              "nombre" => "Elías"
              "apellidos" => "Jatem"
            ]
            2 => array:2 [
              "nombre" => "M. Teresa"
              "apellidos" => "Quiles"
            ]
            3 => array:2 [
              "nombre" => "M. Antonia"
              "apellidos" => "Arbós"
            ]
            4 => array:2 [
              "nombre" => "Elena"
              "apellidos" => "Ostos"
            ]
            5 => array:2 [
              "nombre" => "Helena"
              "apellidos" => "Ostos"
            ]
            6 => array:2 [
              "nombre" => "Naiara"
              "apellidos" => "Valtierra"
            ]
            7 => array:2 [
              "nombre" => "Clara"
              "apellidos" => "Carnicer"
            ]
            8 => array:2 [
              "nombre" => "M. Teresa"
              "apellidos" => "Salcedo"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514053665"
        "doi" => "10.3265/Nefrologia.pre2013.Oct.12272"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514053665?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414053662?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000001/v0_201502091619/X2013251414053662/v0_201502091620/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251414053670"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2013.Nov.12369"
    "estado" => "S300"
    "fechaPublicacion" => "2014-01-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2014;34:34-45"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 18271
      "formatos" => array:3 [
        "EPUB" => 388
        "HTML" => 16370
        "PDF" => 1513
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Consensus document on treatment of type 2 diabetes in patients with chronic kidney disease*"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "34"
          "paginaFinal" => "45"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica#"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "12369_16025_54389_en_f112369_06.jpg"
              "Alto" => 794
              "Ancho" => 2111
              "Tamanyo" => 357598
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Chronic kidney disease staging in accordance with the 2012 Kidney Disease Global Outcomes guidelines"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => " Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica, Ricardo Gómez-Huelgas, Alberto Martínez-Castelao, Sara Artola, José Luis Górriz, José L. Górriz, Edelmiro Menéndez"
          "autores" => array:8 [
            0 => array:1 [
              "apellidos" => "Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica"
            ]
            1 => array:2 [
              "nombre" => "Ricardo"
              "apellidos" => "Gómez-Huelgas"
            ]
            2 => array:2 [
              "nombre" => "Alberto"
              "apellidos" => "Martínez-Castelao"
            ]
            3 => array:2 [
              "nombre" => "Sara"
              "apellidos" => "Artola"
            ]
            4 => array:2 [
              "nombre" => "José Luis"
              "apellidos" => "Górriz"
            ]
            5 => array:2 [
              "nombre" => "José L."
              "apellidos" => "Górriz"
            ]
            6 => array:2 [
              "nombre" => "Edelmiro"
              "apellidos" => "Menéndez"
            ]
            7 => null
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514053673"
        "doi" => "10.3265/Nefrologia.pre2013.Nov.12369"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514053673?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414053670?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000001/v0_201502091619/X2013251414053670/v0_201502091620/en/main.assets"
  ]
  "en" => array:14 [
    "idiomaDefecto" => true
    "titulo" => "Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "46"
        "paginaFinal" => "52"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Alfons Segarra, Elías Jatem, M. Teresa Quiles, M. Antonia Arbós, Elena Ostos, Helena Ostos, Naiara Valtierra, Clara Carnicer, Irene Agraz, M. Teresa Salcedo"
        "autores" => array:10 [
          0 => array:3 [
            "nombre" => "Alfons"
            "apellidos" => "Segarra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:4 [
            "nombre" => "El&#237;as"
            "apellidos" => "Jatem"
            "email" => array:1 [
              0 => "jatemelias&#64;gmail&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "M&#46; Teresa"
            "apellidos" => "Quiles"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "M&#46; Antonia"
            "apellidos" => "Arb&#243;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Elena"
            "apellidos" => "Ostos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Helena"
            "apellidos" => "Ostos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Naiara"
            "apellidos" => "Valtierra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Clara"
            "apellidos" => "Carnicer"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "affe"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Irene"
            "apellidos" => "Agraz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "M&#46; Teresa"
            "apellidos" => "Salcedo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "afff"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:6 [
          0 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Universitari Vall d'Hebron, Barcelona,   "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Escuela de Doctorado, Universidad Autónoma de Barcelona,    "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => " Servicio de Investigación Cirugía, Cirugía. Institut de Recerca Vall d¿Hebron, Barcelona,   "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Universitari Vall d'Hebron, Barcelona,  Spain, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Bioquímica, Hospital Universitari Vall d'Hebron, Barcelona,   "
            "etiqueta" => "<span class="elsevierStyleSup">e</span>"
            "identificador" => "affe"
          ]
          5 => array:3 [
            "entidad" => "Servicio de Anatomía Patológica, Hospital Universitari Vall d'Hebron, Barcelona,   "
            "etiqueta" => "<span class="elsevierStyleSup">f</span>"
            "identificador" => "afff"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Valor diagn&#243;stico de los niveles s&#233;ricos del receptor soluble de la uroquinasa en adultos con s&#237;ndrome nefr&#243;tico idiop&#225;tico"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54357_en_t112256i.jpg"
            "Alto" => 909
            "Ancho" => 2152
            "Tamanyo" => 364798
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Clinical-demographic variables in the patient sample studied"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara">Minimal change disease &#40;MCD&#41;&#44; focal segmental glomerulosclerosis &#40;FSGS&#41; and membranous nephropathy &#40;MN&#41; are the three primary glomerulopathies responsible for most pure nephrotic syndromes in adults&#46;<span class="elsevierStyleSup">1-3</span> The three diseases are similar in presentation&#44; and as such&#44; it is not usually possible to distinguish between them using clinical or biochemical criteria and&#44; in order to obtain an accurate diagnosis&#44; it is necessary to perform a renal biopsy&#46; The presence of a soluble glomerular permeability factor is currently considered the main aetiological factor of primary FSGS&#46;<span class="elsevierStyleSup">4-10</span> In a recent study&#44; Wei et al&#46;<span class="elsevierStyleSup">11</span> identified the soluble urokinase-type plasminogen activator receptor &#40;suPAR&#41; as one of the potential factors responsible for podocyte injury in FSGS and proposed that a serum level higher than 3000pg&#47;ml could be a sensitive and specific biomarker for distinguishing idiopathic FSGS from other nephrotic syndrome forms&#46; However&#44; although the number of patients with MN included in this study was low&#44; some patients with MN displayed suPAR values that were higher than the selected cut-off point&#44; which suggests that suPAR does not allow for adequate differentiation between both diseases&#46; Furthermore&#44; the data of Wei et al&#46; were not reproduced in an independent study that was carried out on a small number of patients&#44; in which no differences were observed in suPAR levels between patients with primary and secondary FSGS and between both forms and patients with minimal change disease&#46;<span class="elsevierStyleSup">12&#44;13</span></p><p class="elsevierStylePara">In a subsequent study&#44; Wei et al&#46;<span class="elsevierStyleSup">14</span> measured suPAR levels in young patients with corticosteroid-resistant FSGS and in patients younger than 18 years of age recruited by the European consortium PodoNet for the corticosteroid-resistant nephrotic syndrome study and they confirmed that&#44; in both groups of patients with FSGS&#44; suPAR values were significantly higher than those of healthy controls&#44; but with a very heterogeneous distribution and a considerable overlapping of values between patients and healthy controls&#46; In the American cohort of the aforementioned study&#44; baseline suPAR levels were independently associated with the glomerular filtration rate&#44; which is similar to the findings of Maas et al&#46;<span class="elsevierStyleSup">12</span>&#44; and with black patients&#44; which suggests that the suPAR value may be different depending on the level of renal function or the ethnic group studied&#46;</p><p class="elsevierStylePara">In a study carried out very recently in China<span class="elsevierStyleSup">15</span> that included both children and adults with idiopathic MN&#44; MCD and secondary FSGS&#44; higher suPAR levels were found in patients with idiopathic FSGS than in the other groups&#44; but suPAR levels did not distinguish between idiopathic FSGS and other glomerulopathies due to the considerable overlapping of values between groups&#46; Furthermore&#44; mean suPAR levels of patients with idiopathic FSGS reported in the aforementioned study were clearly lower than those observed in previous studies&#44;<span class="elsevierStyleSup">11&#44;12</span> which&#44; along with the evidence of racial influence reported in the North American cohort&#44;<span class="elsevierStyleSup">12</span> suggests that there could be ethnic differences in the distribution of suPAR levels or in the pathogenic relationship between suPAR and FSGS&#46; These findings suggest the clinical usefulness of serum suPAR levels with regard to inconclusive FSGS in clinical practice&#46;<span class="elsevierStyleSup">16</span> However&#44; regardless of any potential differences there may be between studies in terms of ethnic&#47;geographic variables&#44; sample size or idiopathic FSGS form classification criteria&#44; the studies carried out to date agree on identifying a patient group with FSGS that present high serum suPAR levels&#44; but the data provided do not allow us to know whether these levels are associated or not with certain clinical characteristics of the disease&#46;</p><p class="elsevierStylePara">In this study&#44; we measured circulating suPAR levels at the time of diagnosis in a cohort of patients with idiopathic nephrotic syndrome caused by MCD&#44; FSGS or MN with the following objectives&#58; 1&#41; To analyse the clinical&#44; biochemical and histopathological variables associated with circulating suPAR levels&#46; 2&#41; To analyse whether serum suPAR level is useful for distinguishing between patients with patients with FSGS and those with MCD and MN&#46; 3&#41; To analyse whether&#44; in patients with idiopathic FSGS&#44; there are differences in the baseline clinical or biochemical characteristics of the disease depending on the circulating suPAR level&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">PATIENTS AND METHOD</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">We included 60 patients &#62;18 years of age with pure nephrotic syndrome&#44; defined by proteinuria &#62;3&#46;5g&#47;day&#44; serum albumin &#60;3&#46;5 g&#47;dl&#44; hyperlipidaemia and oedema&#44; in the absence of haematuria or high blood pressure&#44; secondary to idiopathic FSGS&#44; MCD or MN&#44; diagnosed by renal biopsy&#46; Primary FSGS was diagnosed when there was evidence of typical lesions in the optical microscope &#40;all biopsies were analysed by the same pathologists&#41; and diffuse podocyte effacement in the electron microscope&#44; and after ruling out secondary aetiologies&#44; including&#58; renal mass reduction&#44; morbid obesity&#44; nephropathy associated with human immunodeficiency virus&#44; heroin or cocaine use&#44; infection by parvovirus B19&#44; analgesic&#44; bisphosphonate or interferon use&#44; vesicoureteral reflux or obstructive sleep apnoea&#46; In 4 patients under the age of 30&#44; we carried out a genetic study that ruled out the presence of nephrin or podocin mutations&#46; All patients with FSGS displayed the classic variant &#40;NOS&#41;&#46; In the immunofluorescence study&#44; we detected IgM deposits in 12 patients&#44; C3 deposits in 3&#44; IgM and C3 deposits in 2&#44; and no deposits in 3 patients&#46; Idiopathic MCD was diagnosed when there was an absence of apparent lesions in the optical microscope and the presence of diffuse podocyte fusion in the electron microscope&#44; after ruling out a history of medication use or associated lymphoproliferative processes&#46; MN was diagnosed when there was evidence of characteristic data in the optical microscope and subepithelial IgG and C3 deposits in the immunofluorescence study&#46; In all patients with membranous nephropathy included in the study&#44; we confirmed that antibodies were positive against the phospholipase A2 receptor &#40;anti-PLA2R&#41; and we ruled out potential secondary causes&#44; as per the protocol&#46; When the blood samples were obtained&#44; no patient was receiving treatment with corticosteroids&#44; immunosuppressants&#44; angiotensin II receptor antagonists&#44; aldosterone receptor antagonists or statins&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Methods</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Serum creatinine was measured by the IDMS-traceable compensated method &#40;Hitachi Modular P-800 Roche Diagnostics&#44; Germany&#41;&#46; The estimated glomerular filtration rate &#40;eGFR&#41; was calculated using the CKD-EPI formula&#46;<span class="elsevierStyleSup">17</span> SuPAR levels were measured from serum samples using a commercial ELISA kit &#40;Human uPAR Quantikine<span class="elsevierStyleSup">&#174;</span> ELISA kit&#59; R&#38;D Systems&#44; Minneapolis&#44; MN&#44; USA&#59; intra-assay variability&#58; 4&#46;1&#37;-7&#46;5&#37;&#59; inter-assay variability&#58; 5&#46;1&#37;-5&#46;9&#37;&#41;&#46;<span class="elsevierStyleSup">11</span> To analyse reproducibility of measurements&#44; three or more suPAR measurements were taken during the nephrotic phase before starting treatment in 11 patients and coefficients of variation below 10&#37; were observed&#46; Anti-PLA2R antibodies were measured by a commercial immunofluorescence assay &#40;Anti-Phospholipase A2 receptor IIFT&#59; Euroimmun AG&#44; L&#252;beck&#44; Germany&#41;&#46;<span class="elsevierStyleSup">18&#44;19</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Pathological analysis of renal biopsies</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The biopsies were stained with haematoxylin and eosin&#44; PAS &#40;Periodic acid&#8211;Schiff&#41;- methenamine and Masson&#39;s trichrome for morphological analysis and immunofluorescence studies were carried out with antibodies against IgA&#44; IgG&#44; IgM&#44; C3&#44; fibrinogen and light chains and were processed for an electron microscope study&#46; In biopsies with a MN pattern&#44; we carried out immunohistochemical staining with anti-PLA2R antibodies &#40;HPA012657&#44; Sigma-Aldrich Co&#46;LLC&#46; St Louis&#44; USA&#41;&#46;</p><p class="elsevierStylePara">This study adhered to the parameters established by the Declaration of Helsinki&#46; All patients gave their informed consent in writing and the bioethics committee of the corresponding centre approved the study&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Statistical analysis</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Quantitative variables were expressed as the mean&#160;&#177; 1 standard deviation and the qualitative variables were expressed as a proportion&#46; Group means were compared using the Student&#8217;s t-test for independent data in the case of two means&#44; or variance analysis with the Bonferroni correction for group comparison in the case of more than two means&#46; Categorical variables were compared using the &#967;<span class="elsevierStyleSup">2</span> test&#46; In each separate kidney disease&#44; we analysed the relationship between suPAR levels and demographic and biochemical variables and we considered suPAR concentrations as continuous variables and tertiles&#46; We carried out a variance analysis&#44; ordering the variables studied in tertiles with the aim of identifying the variables that were independently associated with the circulating suPAR level&#46; After analysing the differences between groups&#44; we analysed the sensitivity and specificity of suPAR levels in order to identify patients with FSGS&#44; by ROC curves&#46; We considered <span class="elsevierStyleItalic">P</span> values &#60;&#46;05 to be significant&#46; The statistical calculations were carried out using the SPSS 20&#46;0 software&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Table 1 summarises the clinical and demographic characteristics of the patients included in the study&#46; We did not observe significant differences in terms of distribution by sex between study groups&#46; Patients with MCD were younger and had lower serum albumin levels than patients with FSGS and MN&#46;</p><p class="elsevierStylePara">Patients with FSGS displayed significantly lower eGFR values than in the other two groups and patients with MCD displayed higher eGFR values &#40;FSGS vs&#46; MN&#44; <span class="elsevierStyleItalic">P</span>&#61;&#46;040&#59; FSGS vs&#46; MCD&#44; <span class="elsevierStyleItalic">p</span>&#60;&#46;001&#59; MN vs&#46; MCD&#44; <span class="elsevierStyleItalic">p</span>&#61;&#46;045&#41;</p><p class="elsevierStylePara">No significant differences were observed in suPAR values between sexes in any of the three glomerular disease groups&#46;</p><p class="elsevierStylePara">SuPAR levels of patients with MCD were significantly lower than in patients with FSGS &#40;2668&#46;5&#177;625&#46;8 vs&#46; 3938&#46;9&#177;849pg&#47;ml&#44; <span class="elsevierStyleItalic">p</span>&#60;&#46;001&#41;&#44; but we did not observe significant differences between patients with MN and FSGS &#40;3373&#46;3&#177;1073&#46;1 vs&#46; 3938&#46;9&#177;849pg&#47;ml&#44; <span class="elsevierStyleItalic">p</span>&#61;&#46;127&#41; or between MCD and MN &#40;2668&#177;625&#46;8 vs&#46; 3373&#46;3&#177;1073&#46;1 <span class="elsevierStyleItalic">p</span>&#61;&#46;055&#41; &#40;Figure 1&#41;&#46; In the overall patient sample&#44; suPAR values were correlated positively with age and serum creatinine and negatively with eGFR &#40;Figure 2&#41;&#46; We did not observe statistically significant correlations between suPAR levels and proteinuria&#46;</p><p class="elsevierStylePara">In the variance analysis&#44; we observed that&#44; after adjusting for age and glomerular filtration rate&#44; the only variable significantly associated with suPAR level was the type of glomerular disease and this association was due to patients with MCD having significantly lower suPAR levels than patients with FSGS and MN&#46; Overall&#44; the model explained 26&#46;9&#37; of the variability observed in suPAR levels &#40;F&#58; 4&#46;47&#44; <span class="elsevierStyleItalic">p</span>&#61;&#46;039&#41; &#40;Table 2&#41;&#44; which were not explained by the differences in age and glomerular filtration rate between the groups&#46;</p><p class="elsevierStylePara">After grouping the patients of each glomerular disease group by the respective suPAR tertiles&#44; no significant differences were observed between groups in any of the clinical or biochemical characteristics of the disease at diagnosis &#40;data not displayed&#41;&#46;</p><p class="elsevierStylePara">On analysing the potential diagnostic value of the serum suPAR level for the identification of patients with FSGS in the overall patient group&#44; we observed that a value of 3452pg&#47;ml had a sensitivity of 73&#46;7&#37; and a specificity of 72&#46;5&#37;&#44; with an area under the curve &#40;AUC&#41; of 0&#46;782&#177;0&#46;124&#44; <span class="elsevierStyleItalic">p</span>&#61;&#46;001 &#40;Figure 3&#41;&#46; On analysing the capacity of suPAR to distinguish between patients with FSGS and MCD&#44; after excluding patients with MN from the analysis&#44; we observed that a value &#8805;3442&#46;4pg&#47;ml had a sensitivity of 70&#37; and a specificity of 87&#46;5&#37;&#44; with an AUC of 0&#46;881 &#177; 95&#37; confidence interval &#40;CI&#41; 0&#46;107&#44; <span class="elsevierStyleItalic">p</span>&#60;&#46;001&#46; Values &#8805;3530&#46;9pg&#47;ml had a specificity of 99&#46;93&#37; for distinguishing between the two diseases &#40;Figure 4&#41; at the expense of sensitivity&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The results of our study indicate that circulating suPAR levels are related to the type of kidney disease that causes the nephrotic syndrome&#44; but also to age and renal function&#46; The relationship observed between suPAR levels&#44; age and the glomerular filtration rate coincides with that reported in previous studies&#46;<span class="elsevierStyleSup">11-14</span> In the multivariate analysis&#44; we observed that after making the corresponding adjustments&#44; the only variable with significant association was the type of glomerular disease and the association was due to MCD patients displaying significantly lower suPAR levels than patients with FSGS and MN&#44; without significant differences being observed between the two latter groups&#46; The differences found between FSGS and MCD coincide with those reported in two previous studies&#46;<span class="elsevierStyleSup">11-14</span> Both mean levels and the distribution of suPAR values observed in our FSGS patient group are similar to those reported by Wei et al&#46;<span class="elsevierStyleSup">11</span>&#44; but unlike the latter&#44; our data coincide with those described by Huang<span class="elsevierStyleSup">15</span> in which suPAR levels higher than 3000ng&#47;ml do not allow adequate differentiation between patients with FSGS and patients with the other two glomerular diseases that cause nephrotic syndrome&#46; Patients with MCD displayed a more homogeneous distribution and lower variability in suPAR levels than patients with FSGS and MN&#46; Given the wide dispersion of suPAR values observed in the FSGS patient group&#44; we considered it to be of interest to analyse whether there were differences in the clinical profile of the disease depending on the suPAR level&#44; but we did not find an association between the latter and any clinical or biochemical characteristic studied&#46;</p><p class="elsevierStylePara">Through analysis of ROC curves&#44; we observed that suPAR levels had a low sensitivity and specificity for adequately identifying patients with FSGS mainly due to the high overlapping of values between patients with FSGS and MN on one hand&#44; and between those with MN and MCD on the other&#46;</p><p class="elsevierStylePara">Furthermore&#44; taking into account the existing differences between FSGS and MCD with regard to the prognosis and&#47;or response to treatment and their differences in suPAR levels&#44; we considered it to be of particular interest to analyse the usefulness of suPAR for distinguishing between the two glomerular diseases&#46; Our data indicate that the sensitivity of suPAR in distinguishing between them was low due to the considerable number of patients with FSGS and low suPAR levels&#46; Nevertheless&#44; it was possible to identify a suPAR level with a high specificity &#40;99&#37;&#41; to rule out the diagnosis of MCD&#44; due to the low likelihood of finding a suPAR concentration equal to or greater than 3531ng&#47;ml in MCD&#46; This data&#44; if confirmed in independent studies&#44; could have practical implications in cases in which the renal biopsy is inconclusive or in cases classified as MCD that do not respond to treatment as expected&#46;</p><p class="elsevierStylePara">The main limitation of this study is its sample size&#46; On analysing the distributions in suPAR levels in each group and the differences between groups&#44; it is possible to consider that the inclusion of a higher number of patients&#44; with a reduction in the CI range&#44; could result in a higher sensitivity for distinguishing between FSGS and MCD&#46; However&#44; given the wide dispersion of suPAR levels observed both in FSGS and in MN&#44; although an increase in the sample size would allow detection of significant differences between both&#44; it seems indisputable that a low suPAR value would not allow us to rule out the diagnosis of FSGS&#44; nor would a high suPAR value allow us to rule out MN&#46; Another limitation to bear in mind&#44; which is common to all studies that include patients with both diseases&#44; is the potential classification error between MCD and FSGS&#46; The diagnostic criteria used in this study exclude the possibility of patients with MCD having been classified as FSGS patients&#46; However&#44; due to the focal nature of the lesions&#44; it is not possible to rule out the possibility that some patients with FSGS may have been classified as MCD patients when no segmental sclerosis lesions have been detected in the optical or electron microscopes in the kidney tissue sample available for analysis&#46; Although we are aware of this limitation&#44; we consider it unlikely that this would lead to a systematic error with an important influence on the results&#46;</p><p class="elsevierStylePara">In summary&#44; our data indicate that in patients with nephrotic syndrome caused by MCD&#44; FSGS or MN&#44; after adjusting for age and renal function as the main confounding variables&#44; MCD patients had significantly lower serum suPAR levels than FSGS or MN patients&#46; Despite these differences&#44; the high overlapping of values between groups means that suPAR values alone do not provide useful information in clinical practice for distinguishing between the three types of glomerulopathy&#46; However&#44; once MN has been definitively ruled out as the cause of nephrotic syndrome&#44; in patients for whom there are doubts about whether to diagnose MCD or FSGS due to the presence of inconclusive lesion patterns and when it is not possible to carry out another biopsy&#44; a suPAR level higher than 3531pg&#47;ml could be a useful indicator of a high degree of suspicion of FSGS&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The authors declare that they have no conflicts of interest related to the contents of this article&#46;</p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54357&#95;en&#95;t112256i&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54357_en_t112256i.jpg" alt="Clinical-demographic variables in the patient sample studied "></img></a></p><p class="elsevierStylePara">Table 1&#46; Clinical-demographic variables in the patient sample studied </p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54358&#95;en&#95;t212256i&#95;copy1&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54358_en_t212256i_copy1.jpg" alt="Variables associated with circulating levels of soluble urokinase-type plasminogen activator receptor&#46; ANOVA"></img></a></p><p class="elsevierStylePara">Table 2&#46; Variables associated with circulating levels of soluble urokinase-type plasminogen activator receptor&#46; ANOVA</p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54359&#95;en&#95;f112256i&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54359_en_f112256i.jpg" alt="Levels of soluble urokinase-type plasminogen activator receptor by glomerular disease type "></img></a></p><p class="elsevierStylePara">Figure 1&#46; Levels of soluble urokinase-type plasminogen activator receptor by glomerular disease type </p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54361&#95;en&#95;f212256i&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54361_en_f212256i.jpg" alt="Correlations between serum levels of soluble urokinase-type plasminogen activator receptor&#44; clinical and biochemical variables in the sample "></img></a></p><p class="elsevierStylePara">Figure 2&#46; Correlations between serum levels of soluble urokinase-type plasminogen activator receptor&#44; clinical and biochemical variables in the sample </p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54362&#95;en&#95;f312256i&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54362_en_f312256i.jpg" alt="Soluble urokinase-type plasminogen activator receptor values for identifying patients with idiopathic focal segmental glomerulosclerosis "></img></a></p><p class="elsevierStylePara">Figure 3&#46; Soluble urokinase-type plasminogen activator receptor values for identifying patients with idiopathic focal segmental glomerulosclerosis </p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54363&#95;en&#95;f412256i&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54363_en_f412256i.jpg" alt="ROC curve of soluble urokinase-type plasminogen activator receptor values to distinguish between focal segmental glomerulosclerosis and minimal change disease "></img></a></p><p class="elsevierStylePara">Figure 4&#46; ROC curve of soluble urokinase-type plasminogen activator receptor values to distinguish between focal segmental glomerulosclerosis and minimal change disease </p>"
    "pdfFichero" => "P1-E565-S4482-A12256-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:5 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec439083"
          "palabras" => array:1 [
            0 => "Glomerulonefritis membranosa"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec439085"
          "palabras" => array:1 [
            0 => "Enfermedad de cambios m&#237;nimos"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec439090"
          "palabras" => array:1 [
            0 => "S&#237;ndrome nefr&#243;tico"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec439093"
          "palabras" => array:1 [
            0 => "suPAR"
          ]
        ]
        4 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec439096"
          "palabras" => array:1 [
            0 => "Glomeruloesclerosis focal y segmentaria"
          ]
        ]
      ]
      "en" => array:5 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec439084"
          "palabras" => array:1 [
            0 => "Membranous glomerulonephritis"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec439087"
          "palabras" => array:1 [
            0 => "Minimal change disease"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec439092"
          "palabras" => array:1 [
            0 => "Nephrotic syndrome"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec439094"
          "palabras" => array:1 [
            0 => "suPAR"
          ]
        ]
        4 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec439097"
          "palabras" => array:1 [
            0 => "Focal segmental glomerulosclerosis"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Introducci&#243;n&#58; </span>Estudios recientes sugieren que los niveles del receptor soluble de la uroquinasa &#40;suPAR&#41; podr&#237;an ser &#250;tiles para diferenciar la glomeruloesclerosis focal y segmentaria &#40;GFS&#41; idiop&#225;tica de otras glomerulopat&#237;as causantes de s&#237;ndrome nefr&#243;tico&#44; pero estos datos no han sido confirmados en estudios independientes&#46; El objetivo de nuestro estudio es analizar si los niveles circulantes de suPAR son &#250;tiles para identificar la enfermedad renal primaria en enfermos afectos de s&#237;ndrome nefr&#243;tico secundario a GFS&#44; enfermedad por cambios m&#237;nimos o nefropat&#237;a membranosa &#40;NM&#41; idiop&#225;tica&#46; <span class="elsevierStyleBold">M&#233;todos&#58;</span> Se realizaron mediciones de niveles de suPAR circulante en el momento del diagn&#243;stico en 60 pacientes con s&#237;ndrome nefr&#243;tico secundario a GFS&#44; enfermedad por cambios m&#237;nimos &#40;ECM&#41; y NM&#46; Se analizaron las correlaciones entre niveles de suPAR y variables demogr&#225;ficas&#44; cl&#237;nicas y bioqu&#237;micas&#46; La sensibilidad y la especificidad de suPAR para diferenciar a los enfermos con GFS se analizaron mediante curvas ROC&#46; <span class="elsevierStyleBold">Resultados&#58; </span>Tras ajustar por edad y funci&#243;n renal&#44;<span class="elsevierStyleBold"> </span>los niveles de suPAR fueron significativamente m&#225;s elevados en enfermos con GFS que en ECM &#40;p &#60; 0&#44;001&#41;&#44; pero no hubo diferencias entre GFS y NM &#40;p &#61; 0&#44;12&#41;&#46; Un valor de suPAR &#8805; 3452 pg&#47;ml tuvo una sensibilidad del 73&#44;7&#160;&#37; y una especificidad del 72&#44;5&#160;&#37;&#44; con un &#225;rea bajo la curva &#40;ABC&#41; de 0&#44;782 &#177; 0&#44;124&#44; p &#61; 0&#44;001&#44; para identificar a los enfermos con GFS&#46; Tras excluir a los enfermos con NM&#44; un valor &#8805; 3531 pg&#47;ml tuvo una especificidad del 99&#44;93&#160;&#37; para diferenciar entre ECM y GFS&#46; <span class="elsevierStyleBold">Conclusiones&#58;</span> Los valores de suPAR por s&#237; solos no diferencian entre los tres tipos de glomerulopat&#237;a&#46; Sin embargo&#44; tras excluir el diagn&#243;stico de NM&#44; un nivel de suPAR &#62; 3531 pg&#47;ml podr&#237;a tener una elevada especificidad &#40;pero baja sensibilidad&#41; para el diagn&#243;stico de GFS&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Introduction&#58; </span>Recent studies suggest that<span class="elsevierStyleBold"> </span>soluble urokinase-type plasminogen activator receptor &#40;suPAR&#41; levels could be useful for distinguishing idiopathic focal segmental glomerulosclerosis &#40;FSGS&#41; from other glomerulopathies that cause nephrotic syndrome&#44; but these data have not been confirmed in independent studies&#46; The objective of our study is to analyse whether circulating levels of suPAR are useful for identifying primary kidney disease in patients with nephrotic syndrome secondary to FSGS&#44; minimal change disease or idiopathic membranous nephropathy &#40;MN&#41;&#46; <span class="elsevierStyleBold">Methods&#58;</span> We measured circulating suPAR at diagnosis in 60 patients with nephrotic syndrome secondary to FSGS&#44; minimal change disease &#40;MCD&#41; and membranous nephropathy &#40;MN&#41;&#46; The correlations between suPAR levels and demographic&#44; clinical and biochemical variables were analysed&#46; The sensitivity and specificity of suPAR in distinguishing FSGS patients were analysed by ROC curves&#46; <span class="elsevierStyleBold">Results&#58;</span> After adjusting for age and renal function&#44; suPAR levels were significantly higher in patients with FSGS than in those with MCD &#40;<span class="elsevierStyleItalic">p</span>&#60;&#46;001&#41;&#44; but there were no differences between FSGS and MN &#40;<span class="elsevierStyleItalic">P</span>&#61;&#46;12&#41;&#46; A suPAR value &#8805;3452pg&#47;ml had a sensitivity of 73&#46;7&#37; and a specificity of 72&#46;5&#37;&#44; with an area under the curve &#40;AUC&#41; of 0&#46;782&#177;0&#46;124&#44; <span class="elsevierStyleItalic">p</span>&#61;&#46;001&#44; for identifying patients with FSGS&#46; After excluding patients with MN&#44; a value &#8805;3531pg&#47;ml had a specificity of 99&#46;93&#37; for distinguishing between MCD and FSGS&#46; <span class="elsevierStyleBold">Conclusions&#58;</span> suPAR values alone do not distinguish between the three types of glomerulopathy&#46; Nevertheless&#44; after excluding the diagnosis of MN&#44; a suPAR level &#62;3531pg&#47;ml could have a high specificity &#40;but a low sensitivity&#41; in the diagnosis of FSGS&#46;</p>"
      ]
    ]
    "multimedia" => array:6 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54357_en_t112256i.jpg"
            "Alto" => 909
            "Ancho" => 2152
            "Tamanyo" => 364798
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Clinical-demographic variables in the patient sample studied"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54358_en_t212256i_copy1.jpg"
            "Alto" => 372
            "Ancho" => 2175
            "Tamanyo" => 112356
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Variables associated with circulating levels of soluble urokinase-type plasminogen activator receptor&#46; ANOVA"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54359_en_f112256i.jpg"
            "Alto" => 822
            "Ancho" => 1006
            "Tamanyo" => 116428
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Levels of soluble urokinase-type plasminogen activator receptor by glomerular disease type"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig4"
        "etiqueta" => "Fig. 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54361_en_f212256i.jpg"
            "Alto" => 620
            "Ancho" => 2112
            "Tamanyo" => 172222
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Correlations between serum levels of soluble urokinase-type plasminogen activator receptor&#44; clinical and biochemical variables in the sample"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig5"
        "etiqueta" => "Fig. 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54362_en_f312256i.jpg"
            "Alto" => 1060
            "Ancho" => 1019
            "Tamanyo" => 126453
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Soluble urokinase-type plasminogen activator receptor values for identifying patients with idiopathic focal segmental glomerulosclerosis"
        ]
      ]
      5 => array:8 [
        "identificador" => "fig6"
        "etiqueta" => "Fig. 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54363_en_f412256i.jpg"
            "Alto" => 1070
            "Ancho" => 1001
            "Tamanyo" => 123484
          ]
        ]
        "descripcion" => array:1 [
          "en" => "ROC curve of soluble urokinase-type plasminogen activator receptor values to distinguish between focal segmental glomerulosclerosis and minimal change disease"
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003400000001/v0_201502091619/X2013251414053654/v0_201502091620/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35441"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003400000001/v0_201502091619/X2013251414053654/v0_201502091620/en/P1-E565-S4482-A12256-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414053654?idApp=UINPBA000064"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome
Valor diagnóstico de los niveles séricos del receptor soluble de la uroquinasa en adultos con síndrome nefrótico idiopático
Alfons Segarraa, Elías Jatemb, M. Teresa Quilesc, M. Antonia Arbósc, Elena Ostosd, Helena Ostosa, Naiara Valtierraa, Clara Carnicere, Irene Agraza, M. Teresa Salcedof
a Servicio de Nefrología, Hospital Universitari Vall d'Hebron, Barcelona,
b Escuela de Doctorado, Universidad Autónoma de Barcelona,
c Servicio de Investigación Cirugía, Cirugía. Institut de Recerca Vall d¿Hebron, Barcelona,
d Servicio de Nefrología, Hospital Universitari Vall d'Hebron, Barcelona, Spain,
e Servicio de Bioquímica, Hospital Universitari Vall d'Hebron, Barcelona,
f Servicio de Anatomía Patológica, Hospital Universitari Vall d'Hebron, Barcelona,
Read
10555
Times
was read the article
2896
Total PDF
7659
Total HTML
Share statistics
 array:21 [
  "pii" => "X2013251414053654"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2013.Oct.12256"
  "estado" => "S300"
  "fechaPublicacion" => "2014-01-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia &#40;English Version&#41;. 2014;34:46-52"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 6260
    "formatos" => array:3 [
      "EPUB" => 336
      "HTML" => 5109
      "PDF" => 815
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699514053657"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2013.Oct.12256"
      "estado" => "S300"
      "fechaPublicacion" => "2014-01-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2014;34:46-52"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 12049
        "formatos" => array:3 [
          "EPUB" => 339
          "HTML" => 10822
          "PDF" => 888
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "Valor diagn&#243;stico de los niveles s&#233;ricos del receptor soluble de la uroquinasa en adultos con s&#237;ndrome nefr&#243;tico idiop&#225;tico"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "46"
            "paginaFinal" => "52"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig1"
            "etiqueta" => "Tab.  2"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier Espa&#241;a"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "12256_19904_50074_es_12256_t2.jpg"
                "Alto" => 107
                "Ancho" => 600
                "Tamanyo" => 55813
              ]
            ]
            "descripcion" => array:1 [
              "es" => "Variables asociadas a niveles circulantes de receptor soluble de la uroquinasa&#46; ANOVA"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Alfons Segarra, El&#237;as Jatem, M&#46; Teresa Quiles, M&#46; Antonia Arb&#243;s, Elena Ostos, Helena Ostos, Naiara Valtierra, Clara Carnicer, Irene Agraz, M&#46; Teresa Salcedo"
            "autores" => array:10 [
              0 => array:2 [
                "nombre" => "Alfons"
                "apellidos" => "Segarra"
              ]
              1 => array:2 [
                "nombre" => "El&#237;as"
                "apellidos" => "Jatem"
              ]
              2 => array:2 [
                "nombre" => "M&#46; Teresa"
                "apellidos" => "Quiles"
              ]
              3 => array:2 [
                "nombre" => "M&#46; Antonia"
                "apellidos" => "Arb&#243;s"
              ]
              4 => array:2 [
                "nombre" => "Elena"
                "apellidos" => "Ostos"
              ]
              5 => array:2 [
                "nombre" => "Helena"
                "apellidos" => "Ostos"
              ]
              6 => array:2 [
                "nombre" => "Naiara"
                "apellidos" => "Valtierra"
              ]
              7 => array:2 [
                "nombre" => "Clara"
                "apellidos" => "Carnicer"
              ]
              8 => array:2 [
                "nombre" => "Irene"
                "apellidos" => "Agraz"
              ]
              9 => array:2 [
                "nombre" => "M&#46; Teresa"
                "apellidos" => "Salcedo"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251414053654"
          "doi" => "10.3265/Nefrologia.pre2013.Oct.12256"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414053654?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514053657?idApp=UINPBA000064"
      "url" => "/02116995/0000003400000001/v0_201502091353/X0211699514053657/v0_201502091353/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251414053662"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2013.Oct.12272"
    "estado" => "S300"
    "fechaPublicacion" => "2014-01-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2014;34:53-61"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5868
      "formatos" => array:3 [
        "EPUB" => 287
        "HTML" => 4826
        "PDF" => 755
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "53"
          "paginaFinal" => "61"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Valor de los niveles s&#233;ricos del receptor soluble de la uroquinasa en el diagn&#243;stico diferencial entre glomeruloesclerosis focal y segmentaria idiop&#225;tica y secundaria"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "12272_16025_54379_en_t112272i.jpg"
              "Alto" => 1265
              "Ancho" => 2168
              "Tamanyo" => 479310
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Clinical-demographic variables according to patient groups"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Alfons Segarra, El&#237;as Jatem, M&#46; Teresa Quiles, M&#46; Antonia Arb&#243;s, Elena Ostos, Helena Ostos, Naiara Valtierra, Clara Carnicer, M&#46; Teresa Salcedo"
          "autores" => array:9 [
            0 => array:2 [
              "nombre" => "Alfons"
              "apellidos" => "Segarra"
            ]
            1 => array:2 [
              "nombre" => "El&#237;as"
              "apellidos" => "Jatem"
            ]
            2 => array:2 [
              "nombre" => "M&#46; Teresa"
              "apellidos" => "Quiles"
            ]
            3 => array:2 [
              "nombre" => "M&#46; Antonia"
              "apellidos" => "Arb&#243;s"
            ]
            4 => array:2 [
              "nombre" => "Elena"
              "apellidos" => "Ostos"
            ]
            5 => array:2 [
              "nombre" => "Helena"
              "apellidos" => "Ostos"
            ]
            6 => array:2 [
              "nombre" => "Naiara"
              "apellidos" => "Valtierra"
            ]
            7 => array:2 [
              "nombre" => "Clara"
              "apellidos" => "Carnicer"
            ]
            8 => array:2 [
              "nombre" => "M&#46; Teresa"
              "apellidos" => "Salcedo"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514053665"
        "doi" => "10.3265/Nefrologia.pre2013.Oct.12272"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514053665?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414053662?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000001/v0_201502091619/X2013251414053662/v0_201502091620/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251414053670"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2013.Nov.12369"
    "estado" => "S300"
    "fechaPublicacion" => "2014-01-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2014;34:34-45"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 18271
      "formatos" => array:3 [
        "EPUB" => 388
        "HTML" => 16370
        "PDF" => 1513
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Consensus document on treatment of type 2 diabetes in patients with chronic kidney disease&#42;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "34"
          "paginaFinal" => "45"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal cr&#243;nica&#35;"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "12369_16025_54389_en_f112369_06.jpg"
              "Alto" => 794
              "Ancho" => 2111
              "Tamanyo" => 357598
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Chronic kidney disease staging in accordance with the 2012 Kidney Disease Global Outcomes guidelines"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => " Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal cr&#243;nica, Ricardo G&#243;mez-Huelgas, Alberto Mart&#237;nez-Castelao, Sara Artola, Jos&#233; Luis G&#243;rriz, Jos&#233; L&#46; G&#243;rriz, Edelmiro Men&#233;ndez"
          "autores" => array:8 [
            0 => array:1 [
              "apellidos" => "Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal cr&#243;nica"
            ]
            1 => array:2 [
              "nombre" => "Ricardo"
              "apellidos" => "G&#243;mez-Huelgas"
            ]
            2 => array:2 [
              "nombre" => "Alberto"
              "apellidos" => "Mart&#237;nez-Castelao"
            ]
            3 => array:2 [
              "nombre" => "Sara"
              "apellidos" => "Artola"
            ]
            4 => array:2 [
              "nombre" => "Jos&#233; Luis"
              "apellidos" => "G&#243;rriz"
            ]
            5 => array:2 [
              "nombre" => "Jos&#233; L&#46;"
              "apellidos" => "G&#243;rriz"
            ]
            6 => array:2 [
              "nombre" => "Edelmiro"
              "apellidos" => "Men&#233;ndez"
            ]
            7 => null
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514053673"
        "doi" => "10.3265/Nefrologia.pre2013.Nov.12369"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514053673?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414053670?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000001/v0_201502091619/X2013251414053670/v0_201502091620/en/main.assets"
  ]
  "en" => array:14 [
    "idiomaDefecto" => true
    "titulo" => "Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "46"
        "paginaFinal" => "52"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Alfons Segarra, El&#237;as Jatem, M&#46; Teresa Quiles, M&#46; Antonia Arb&#243;s, Elena Ostos, Helena Ostos, Naiara Valtierra, Clara Carnicer, Irene Agraz, M&#46; Teresa Salcedo"
        "autores" => array:10 [
          0 => array:3 [
            "nombre" => "Alfons"
            "apellidos" => "Segarra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:4 [
            "nombre" => "El&#237;as"
            "apellidos" => "Jatem"
            "email" => array:1 [
              0 => "jatemelias&#64;gmail&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "M&#46; Teresa"
            "apellidos" => "Quiles"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "M&#46; Antonia"
            "apellidos" => "Arb&#243;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Elena"
            "apellidos" => "Ostos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Helena"
            "apellidos" => "Ostos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Naiara"
            "apellidos" => "Valtierra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Clara"
            "apellidos" => "Carnicer"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "affe"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Irene"
            "apellidos" => "Agraz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "M&#46; Teresa"
            "apellidos" => "Salcedo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "afff"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:6 [
          0 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Universitari Vall d'Hebron, Barcelona,   "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Escuela de Doctorado, Universidad Autónoma de Barcelona,    "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => " Servicio de Investigación Cirugía, Cirugía. Institut de Recerca Vall d¿Hebron, Barcelona,   "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Universitari Vall d'Hebron, Barcelona,  Spain, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Bioquímica, Hospital Universitari Vall d'Hebron, Barcelona,   "
            "etiqueta" => "<span class="elsevierStyleSup">e</span>"
            "identificador" => "affe"
          ]
          5 => array:3 [
            "entidad" => "Servicio de Anatomía Patológica, Hospital Universitari Vall d'Hebron, Barcelona,   "
            "etiqueta" => "<span class="elsevierStyleSup">f</span>"
            "identificador" => "afff"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Valor diagn&#243;stico de los niveles s&#233;ricos del receptor soluble de la uroquinasa en adultos con s&#237;ndrome nefr&#243;tico idiop&#225;tico"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54357_en_t112256i.jpg"
            "Alto" => 909
            "Ancho" => 2152
            "Tamanyo" => 364798
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Clinical-demographic variables in the patient sample studied"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara">Minimal change disease &#40;MCD&#41;&#44; focal segmental glomerulosclerosis &#40;FSGS&#41; and membranous nephropathy &#40;MN&#41; are the three primary glomerulopathies responsible for most pure nephrotic syndromes in adults&#46;<span class="elsevierStyleSup">1-3</span> The three diseases are similar in presentation&#44; and as such&#44; it is not usually possible to distinguish between them using clinical or biochemical criteria and&#44; in order to obtain an accurate diagnosis&#44; it is necessary to perform a renal biopsy&#46; The presence of a soluble glomerular permeability factor is currently considered the main aetiological factor of primary FSGS&#46;<span class="elsevierStyleSup">4-10</span> In a recent study&#44; Wei et al&#46;<span class="elsevierStyleSup">11</span> identified the soluble urokinase-type plasminogen activator receptor &#40;suPAR&#41; as one of the potential factors responsible for podocyte injury in FSGS and proposed that a serum level higher than 3000pg&#47;ml could be a sensitive and specific biomarker for distinguishing idiopathic FSGS from other nephrotic syndrome forms&#46; However&#44; although the number of patients with MN included in this study was low&#44; some patients with MN displayed suPAR values that were higher than the selected cut-off point&#44; which suggests that suPAR does not allow for adequate differentiation between both diseases&#46; Furthermore&#44; the data of Wei et al&#46; were not reproduced in an independent study that was carried out on a small number of patients&#44; in which no differences were observed in suPAR levels between patients with primary and secondary FSGS and between both forms and patients with minimal change disease&#46;<span class="elsevierStyleSup">12&#44;13</span></p><p class="elsevierStylePara">In a subsequent study&#44; Wei et al&#46;<span class="elsevierStyleSup">14</span> measured suPAR levels in young patients with corticosteroid-resistant FSGS and in patients younger than 18 years of age recruited by the European consortium PodoNet for the corticosteroid-resistant nephrotic syndrome study and they confirmed that&#44; in both groups of patients with FSGS&#44; suPAR values were significantly higher than those of healthy controls&#44; but with a very heterogeneous distribution and a considerable overlapping of values between patients and healthy controls&#46; In the American cohort of the aforementioned study&#44; baseline suPAR levels were independently associated with the glomerular filtration rate&#44; which is similar to the findings of Maas et al&#46;<span class="elsevierStyleSup">12</span>&#44; and with black patients&#44; which suggests that the suPAR value may be different depending on the level of renal function or the ethnic group studied&#46;</p><p class="elsevierStylePara">In a study carried out very recently in China<span class="elsevierStyleSup">15</span> that included both children and adults with idiopathic MN&#44; MCD and secondary FSGS&#44; higher suPAR levels were found in patients with idiopathic FSGS than in the other groups&#44; but suPAR levels did not distinguish between idiopathic FSGS and other glomerulopathies due to the considerable overlapping of values between groups&#46; Furthermore&#44; mean suPAR levels of patients with idiopathic FSGS reported in the aforementioned study were clearly lower than those observed in previous studies&#44;<span class="elsevierStyleSup">11&#44;12</span> which&#44; along with the evidence of racial influence reported in the North American cohort&#44;<span class="elsevierStyleSup">12</span> suggests that there could be ethnic differences in the distribution of suPAR levels or in the pathogenic relationship between suPAR and FSGS&#46; These findings suggest the clinical usefulness of serum suPAR levels with regard to inconclusive FSGS in clinical practice&#46;<span class="elsevierStyleSup">16</span> However&#44; regardless of any potential differences there may be between studies in terms of ethnic&#47;geographic variables&#44; sample size or idiopathic FSGS form classification criteria&#44; the studies carried out to date agree on identifying a patient group with FSGS that present high serum suPAR levels&#44; but the data provided do not allow us to know whether these levels are associated or not with certain clinical characteristics of the disease&#46;</p><p class="elsevierStylePara">In this study&#44; we measured circulating suPAR levels at the time of diagnosis in a cohort of patients with idiopathic nephrotic syndrome caused by MCD&#44; FSGS or MN with the following objectives&#58; 1&#41; To analyse the clinical&#44; biochemical and histopathological variables associated with circulating suPAR levels&#46; 2&#41; To analyse whether serum suPAR level is useful for distinguishing between patients with patients with FSGS and those with MCD and MN&#46; 3&#41; To analyse whether&#44; in patients with idiopathic FSGS&#44; there are differences in the baseline clinical or biochemical characteristics of the disease depending on the circulating suPAR level&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">PATIENTS AND METHOD</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">We included 60 patients &#62;18 years of age with pure nephrotic syndrome&#44; defined by proteinuria &#62;3&#46;5g&#47;day&#44; serum albumin &#60;3&#46;5 g&#47;dl&#44; hyperlipidaemia and oedema&#44; in the absence of haematuria or high blood pressure&#44; secondary to idiopathic FSGS&#44; MCD or MN&#44; diagnosed by renal biopsy&#46; Primary FSGS was diagnosed when there was evidence of typical lesions in the optical microscope &#40;all biopsies were analysed by the same pathologists&#41; and diffuse podocyte effacement in the electron microscope&#44; and after ruling out secondary aetiologies&#44; including&#58; renal mass reduction&#44; morbid obesity&#44; nephropathy associated with human immunodeficiency virus&#44; heroin or cocaine use&#44; infection by parvovirus B19&#44; analgesic&#44; bisphosphonate or interferon use&#44; vesicoureteral reflux or obstructive sleep apnoea&#46; In 4 patients under the age of 30&#44; we carried out a genetic study that ruled out the presence of nephrin or podocin mutations&#46; All patients with FSGS displayed the classic variant &#40;NOS&#41;&#46; In the immunofluorescence study&#44; we detected IgM deposits in 12 patients&#44; C3 deposits in 3&#44; IgM and C3 deposits in 2&#44; and no deposits in 3 patients&#46; Idiopathic MCD was diagnosed when there was an absence of apparent lesions in the optical microscope and the presence of diffuse podocyte fusion in the electron microscope&#44; after ruling out a history of medication use or associated lymphoproliferative processes&#46; MN was diagnosed when there was evidence of characteristic data in the optical microscope and subepithelial IgG and C3 deposits in the immunofluorescence study&#46; In all patients with membranous nephropathy included in the study&#44; we confirmed that antibodies were positive against the phospholipase A2 receptor &#40;anti-PLA2R&#41; and we ruled out potential secondary causes&#44; as per the protocol&#46; When the blood samples were obtained&#44; no patient was receiving treatment with corticosteroids&#44; immunosuppressants&#44; angiotensin II receptor antagonists&#44; aldosterone receptor antagonists or statins&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Methods</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Serum creatinine was measured by the IDMS-traceable compensated method &#40;Hitachi Modular P-800 Roche Diagnostics&#44; Germany&#41;&#46; The estimated glomerular filtration rate &#40;eGFR&#41; was calculated using the CKD-EPI formula&#46;<span class="elsevierStyleSup">17</span> SuPAR levels were measured from serum samples using a commercial ELISA kit &#40;Human uPAR Quantikine<span class="elsevierStyleSup">&#174;</span> ELISA kit&#59; R&#38;D Systems&#44; Minneapolis&#44; MN&#44; USA&#59; intra-assay variability&#58; 4&#46;1&#37;-7&#46;5&#37;&#59; inter-assay variability&#58; 5&#46;1&#37;-5&#46;9&#37;&#41;&#46;<span class="elsevierStyleSup">11</span> To analyse reproducibility of measurements&#44; three or more suPAR measurements were taken during the nephrotic phase before starting treatment in 11 patients and coefficients of variation below 10&#37; were observed&#46; Anti-PLA2R antibodies were measured by a commercial immunofluorescence assay &#40;Anti-Phospholipase A2 receptor IIFT&#59; Euroimmun AG&#44; L&#252;beck&#44; Germany&#41;&#46;<span class="elsevierStyleSup">18&#44;19</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Pathological analysis of renal biopsies</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The biopsies were stained with haematoxylin and eosin&#44; PAS &#40;Periodic acid&#8211;Schiff&#41;- methenamine and Masson&#39;s trichrome for morphological analysis and immunofluorescence studies were carried out with antibodies against IgA&#44; IgG&#44; IgM&#44; C3&#44; fibrinogen and light chains and were processed for an electron microscope study&#46; In biopsies with a MN pattern&#44; we carried out immunohistochemical staining with anti-PLA2R antibodies &#40;HPA012657&#44; Sigma-Aldrich Co&#46;LLC&#46; St Louis&#44; USA&#41;&#46;</p><p class="elsevierStylePara">This study adhered to the parameters established by the Declaration of Helsinki&#46; All patients gave their informed consent in writing and the bioethics committee of the corresponding centre approved the study&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Statistical analysis</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Quantitative variables were expressed as the mean&#160;&#177; 1 standard deviation and the qualitative variables were expressed as a proportion&#46; Group means were compared using the Student&#8217;s t-test for independent data in the case of two means&#44; or variance analysis with the Bonferroni correction for group comparison in the case of more than two means&#46; Categorical variables were compared using the &#967;<span class="elsevierStyleSup">2</span> test&#46; In each separate kidney disease&#44; we analysed the relationship between suPAR levels and demographic and biochemical variables and we considered suPAR concentrations as continuous variables and tertiles&#46; We carried out a variance analysis&#44; ordering the variables studied in tertiles with the aim of identifying the variables that were independently associated with the circulating suPAR level&#46; After analysing the differences between groups&#44; we analysed the sensitivity and specificity of suPAR levels in order to identify patients with FSGS&#44; by ROC curves&#46; We considered <span class="elsevierStyleItalic">P</span> values &#60;&#46;05 to be significant&#46; The statistical calculations were carried out using the SPSS 20&#46;0 software&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Table 1 summarises the clinical and demographic characteristics of the patients included in the study&#46; We did not observe significant differences in terms of distribution by sex between study groups&#46; Patients with MCD were younger and had lower serum albumin levels than patients with FSGS and MN&#46;</p><p class="elsevierStylePara">Patients with FSGS displayed significantly lower eGFR values than in the other two groups and patients with MCD displayed higher eGFR values &#40;FSGS vs&#46; MN&#44; <span class="elsevierStyleItalic">P</span>&#61;&#46;040&#59; FSGS vs&#46; MCD&#44; <span class="elsevierStyleItalic">p</span>&#60;&#46;001&#59; MN vs&#46; MCD&#44; <span class="elsevierStyleItalic">p</span>&#61;&#46;045&#41;</p><p class="elsevierStylePara">No significant differences were observed in suPAR values between sexes in any of the three glomerular disease groups&#46;</p><p class="elsevierStylePara">SuPAR levels of patients with MCD were significantly lower than in patients with FSGS &#40;2668&#46;5&#177;625&#46;8 vs&#46; 3938&#46;9&#177;849pg&#47;ml&#44; <span class="elsevierStyleItalic">p</span>&#60;&#46;001&#41;&#44; but we did not observe significant differences between patients with MN and FSGS &#40;3373&#46;3&#177;1073&#46;1 vs&#46; 3938&#46;9&#177;849pg&#47;ml&#44; <span class="elsevierStyleItalic">p</span>&#61;&#46;127&#41; or between MCD and MN &#40;2668&#177;625&#46;8 vs&#46; 3373&#46;3&#177;1073&#46;1 <span class="elsevierStyleItalic">p</span>&#61;&#46;055&#41; &#40;Figure 1&#41;&#46; In the overall patient sample&#44; suPAR values were correlated positively with age and serum creatinine and negatively with eGFR &#40;Figure 2&#41;&#46; We did not observe statistically significant correlations between suPAR levels and proteinuria&#46;</p><p class="elsevierStylePara">In the variance analysis&#44; we observed that&#44; after adjusting for age and glomerular filtration rate&#44; the only variable significantly associated with suPAR level was the type of glomerular disease and this association was due to patients with MCD having significantly lower suPAR levels than patients with FSGS and MN&#46; Overall&#44; the model explained 26&#46;9&#37; of the variability observed in suPAR levels &#40;F&#58; 4&#46;47&#44; <span class="elsevierStyleItalic">p</span>&#61;&#46;039&#41; &#40;Table 2&#41;&#44; which were not explained by the differences in age and glomerular filtration rate between the groups&#46;</p><p class="elsevierStylePara">After grouping the patients of each glomerular disease group by the respective suPAR tertiles&#44; no significant differences were observed between groups in any of the clinical or biochemical characteristics of the disease at diagnosis &#40;data not displayed&#41;&#46;</p><p class="elsevierStylePara">On analysing the potential diagnostic value of the serum suPAR level for the identification of patients with FSGS in the overall patient group&#44; we observed that a value of 3452pg&#47;ml had a sensitivity of 73&#46;7&#37; and a specificity of 72&#46;5&#37;&#44; with an area under the curve &#40;AUC&#41; of 0&#46;782&#177;0&#46;124&#44; <span class="elsevierStyleItalic">p</span>&#61;&#46;001 &#40;Figure 3&#41;&#46; On analysing the capacity of suPAR to distinguish between patients with FSGS and MCD&#44; after excluding patients with MN from the analysis&#44; we observed that a value &#8805;3442&#46;4pg&#47;ml had a sensitivity of 70&#37; and a specificity of 87&#46;5&#37;&#44; with an AUC of 0&#46;881 &#177; 95&#37; confidence interval &#40;CI&#41; 0&#46;107&#44; <span class="elsevierStyleItalic">p</span>&#60;&#46;001&#46; Values &#8805;3530&#46;9pg&#47;ml had a specificity of 99&#46;93&#37; for distinguishing between the two diseases &#40;Figure 4&#41; at the expense of sensitivity&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The results of our study indicate that circulating suPAR levels are related to the type of kidney disease that causes the nephrotic syndrome&#44; but also to age and renal function&#46; The relationship observed between suPAR levels&#44; age and the glomerular filtration rate coincides with that reported in previous studies&#46;<span class="elsevierStyleSup">11-14</span> In the multivariate analysis&#44; we observed that after making the corresponding adjustments&#44; the only variable with significant association was the type of glomerular disease and the association was due to MCD patients displaying significantly lower suPAR levels than patients with FSGS and MN&#44; without significant differences being observed between the two latter groups&#46; The differences found between FSGS and MCD coincide with those reported in two previous studies&#46;<span class="elsevierStyleSup">11-14</span> Both mean levels and the distribution of suPAR values observed in our FSGS patient group are similar to those reported by Wei et al&#46;<span class="elsevierStyleSup">11</span>&#44; but unlike the latter&#44; our data coincide with those described by Huang<span class="elsevierStyleSup">15</span> in which suPAR levels higher than 3000ng&#47;ml do not allow adequate differentiation between patients with FSGS and patients with the other two glomerular diseases that cause nephrotic syndrome&#46; Patients with MCD displayed a more homogeneous distribution and lower variability in suPAR levels than patients with FSGS and MN&#46; Given the wide dispersion of suPAR values observed in the FSGS patient group&#44; we considered it to be of interest to analyse whether there were differences in the clinical profile of the disease depending on the suPAR level&#44; but we did not find an association between the latter and any clinical or biochemical characteristic studied&#46;</p><p class="elsevierStylePara">Through analysis of ROC curves&#44; we observed that suPAR levels had a low sensitivity and specificity for adequately identifying patients with FSGS mainly due to the high overlapping of values between patients with FSGS and MN on one hand&#44; and between those with MN and MCD on the other&#46;</p><p class="elsevierStylePara">Furthermore&#44; taking into account the existing differences between FSGS and MCD with regard to the prognosis and&#47;or response to treatment and their differences in suPAR levels&#44; we considered it to be of particular interest to analyse the usefulness of suPAR for distinguishing between the two glomerular diseases&#46; Our data indicate that the sensitivity of suPAR in distinguishing between them was low due to the considerable number of patients with FSGS and low suPAR levels&#46; Nevertheless&#44; it was possible to identify a suPAR level with a high specificity &#40;99&#37;&#41; to rule out the diagnosis of MCD&#44; due to the low likelihood of finding a suPAR concentration equal to or greater than 3531ng&#47;ml in MCD&#46; This data&#44; if confirmed in independent studies&#44; could have practical implications in cases in which the renal biopsy is inconclusive or in cases classified as MCD that do not respond to treatment as expected&#46;</p><p class="elsevierStylePara">The main limitation of this study is its sample size&#46; On analysing the distributions in suPAR levels in each group and the differences between groups&#44; it is possible to consider that the inclusion of a higher number of patients&#44; with a reduction in the CI range&#44; could result in a higher sensitivity for distinguishing between FSGS and MCD&#46; However&#44; given the wide dispersion of suPAR levels observed both in FSGS and in MN&#44; although an increase in the sample size would allow detection of significant differences between both&#44; it seems indisputable that a low suPAR value would not allow us to rule out the diagnosis of FSGS&#44; nor would a high suPAR value allow us to rule out MN&#46; Another limitation to bear in mind&#44; which is common to all studies that include patients with both diseases&#44; is the potential classification error between MCD and FSGS&#46; The diagnostic criteria used in this study exclude the possibility of patients with MCD having been classified as FSGS patients&#46; However&#44; due to the focal nature of the lesions&#44; it is not possible to rule out the possibility that some patients with FSGS may have been classified as MCD patients when no segmental sclerosis lesions have been detected in the optical or electron microscopes in the kidney tissue sample available for analysis&#46; Although we are aware of this limitation&#44; we consider it unlikely that this would lead to a systematic error with an important influence on the results&#46;</p><p class="elsevierStylePara">In summary&#44; our data indicate that in patients with nephrotic syndrome caused by MCD&#44; FSGS or MN&#44; after adjusting for age and renal function as the main confounding variables&#44; MCD patients had significantly lower serum suPAR levels than FSGS or MN patients&#46; Despite these differences&#44; the high overlapping of values between groups means that suPAR values alone do not provide useful information in clinical practice for distinguishing between the three types of glomerulopathy&#46; However&#44; once MN has been definitively ruled out as the cause of nephrotic syndrome&#44; in patients for whom there are doubts about whether to diagnose MCD or FSGS due to the presence of inconclusive lesion patterns and when it is not possible to carry out another biopsy&#44; a suPAR level higher than 3531pg&#47;ml could be a useful indicator of a high degree of suspicion of FSGS&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The authors declare that they have no conflicts of interest related to the contents of this article&#46;</p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54357&#95;en&#95;t112256i&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54357_en_t112256i.jpg" alt="Clinical-demographic variables in the patient sample studied "></img></a></p><p class="elsevierStylePara">Table 1&#46; Clinical-demographic variables in the patient sample studied </p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54358&#95;en&#95;t212256i&#95;copy1&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54358_en_t212256i_copy1.jpg" alt="Variables associated with circulating levels of soluble urokinase-type plasminogen activator receptor&#46; ANOVA"></img></a></p><p class="elsevierStylePara">Table 2&#46; Variables associated with circulating levels of soluble urokinase-type plasminogen activator receptor&#46; ANOVA</p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54359&#95;en&#95;f112256i&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54359_en_f112256i.jpg" alt="Levels of soluble urokinase-type plasminogen activator receptor by glomerular disease type "></img></a></p><p class="elsevierStylePara">Figure 1&#46; Levels of soluble urokinase-type plasminogen activator receptor by glomerular disease type </p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54361&#95;en&#95;f212256i&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54361_en_f212256i.jpg" alt="Correlations between serum levels of soluble urokinase-type plasminogen activator receptor&#44; clinical and biochemical variables in the sample "></img></a></p><p class="elsevierStylePara">Figure 2&#46; Correlations between serum levels of soluble urokinase-type plasminogen activator receptor&#44; clinical and biochemical variables in the sample </p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54362&#95;en&#95;f312256i&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54362_en_f312256i.jpg" alt="Soluble urokinase-type plasminogen activator receptor values for identifying patients with idiopathic focal segmental glomerulosclerosis "></img></a></p><p class="elsevierStylePara">Figure 3&#46; Soluble urokinase-type plasminogen activator receptor values for identifying patients with idiopathic focal segmental glomerulosclerosis </p><p class="elsevierStylePara"><a href="grande&#47;12256&#95;16025&#95;54363&#95;en&#95;f412256i&#46;jpg" class="elsevierStyleCrossRefs"><img src="12256_16025_54363_en_f412256i.jpg" alt="ROC curve of soluble urokinase-type plasminogen activator receptor values to distinguish between focal segmental glomerulosclerosis and minimal change disease "></img></a></p><p class="elsevierStylePara">Figure 4&#46; ROC curve of soluble urokinase-type plasminogen activator receptor values to distinguish between focal segmental glomerulosclerosis and minimal change disease </p>"
    "pdfFichero" => "P1-E565-S4482-A12256-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:5 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec439083"
          "palabras" => array:1 [
            0 => "Glomerulonefritis membranosa"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec439085"
          "palabras" => array:1 [
            0 => "Enfermedad de cambios m&#237;nimos"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec439090"
          "palabras" => array:1 [
            0 => "S&#237;ndrome nefr&#243;tico"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec439093"
          "palabras" => array:1 [
            0 => "suPAR"
          ]
        ]
        4 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec439096"
          "palabras" => array:1 [
            0 => "Glomeruloesclerosis focal y segmentaria"
          ]
        ]
      ]
      "en" => array:5 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec439084"
          "palabras" => array:1 [
            0 => "Membranous glomerulonephritis"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec439087"
          "palabras" => array:1 [
            0 => "Minimal change disease"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec439092"
          "palabras" => array:1 [
            0 => "Nephrotic syndrome"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec439094"
          "palabras" => array:1 [
            0 => "suPAR"
          ]
        ]
        4 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec439097"
          "palabras" => array:1 [
            0 => "Focal segmental glomerulosclerosis"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Introducci&#243;n&#58; </span>Estudios recientes sugieren que los niveles del receptor soluble de la uroquinasa &#40;suPAR&#41; podr&#237;an ser &#250;tiles para diferenciar la glomeruloesclerosis focal y segmentaria &#40;GFS&#41; idiop&#225;tica de otras glomerulopat&#237;as causantes de s&#237;ndrome nefr&#243;tico&#44; pero estos datos no han sido confirmados en estudios independientes&#46; El objetivo de nuestro estudio es analizar si los niveles circulantes de suPAR son &#250;tiles para identificar la enfermedad renal primaria en enfermos afectos de s&#237;ndrome nefr&#243;tico secundario a GFS&#44; enfermedad por cambios m&#237;nimos o nefropat&#237;a membranosa &#40;NM&#41; idiop&#225;tica&#46; <span class="elsevierStyleBold">M&#233;todos&#58;</span> Se realizaron mediciones de niveles de suPAR circulante en el momento del diagn&#243;stico en 60 pacientes con s&#237;ndrome nefr&#243;tico secundario a GFS&#44; enfermedad por cambios m&#237;nimos &#40;ECM&#41; y NM&#46; Se analizaron las correlaciones entre niveles de suPAR y variables demogr&#225;ficas&#44; cl&#237;nicas y bioqu&#237;micas&#46; La sensibilidad y la especificidad de suPAR para diferenciar a los enfermos con GFS se analizaron mediante curvas ROC&#46; <span class="elsevierStyleBold">Resultados&#58; </span>Tras ajustar por edad y funci&#243;n renal&#44;<span class="elsevierStyleBold"> </span>los niveles de suPAR fueron significativamente m&#225;s elevados en enfermos con GFS que en ECM &#40;p &#60; 0&#44;001&#41;&#44; pero no hubo diferencias entre GFS y NM &#40;p &#61; 0&#44;12&#41;&#46; Un valor de suPAR &#8805; 3452 pg&#47;ml tuvo una sensibilidad del 73&#44;7&#160;&#37; y una especificidad del 72&#44;5&#160;&#37;&#44; con un &#225;rea bajo la curva &#40;ABC&#41; de 0&#44;782 &#177; 0&#44;124&#44; p &#61; 0&#44;001&#44; para identificar a los enfermos con GFS&#46; Tras excluir a los enfermos con NM&#44; un valor &#8805; 3531 pg&#47;ml tuvo una especificidad del 99&#44;93&#160;&#37; para diferenciar entre ECM y GFS&#46; <span class="elsevierStyleBold">Conclusiones&#58;</span> Los valores de suPAR por s&#237; solos no diferencian entre los tres tipos de glomerulopat&#237;a&#46; Sin embargo&#44; tras excluir el diagn&#243;stico de NM&#44; un nivel de suPAR &#62; 3531 pg&#47;ml podr&#237;a tener una elevada especificidad &#40;pero baja sensibilidad&#41; para el diagn&#243;stico de GFS&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Introduction&#58; </span>Recent studies suggest that<span class="elsevierStyleBold"> </span>soluble urokinase-type plasminogen activator receptor &#40;suPAR&#41; levels could be useful for distinguishing idiopathic focal segmental glomerulosclerosis &#40;FSGS&#41; from other glomerulopathies that cause nephrotic syndrome&#44; but these data have not been confirmed in independent studies&#46; The objective of our study is to analyse whether circulating levels of suPAR are useful for identifying primary kidney disease in patients with nephrotic syndrome secondary to FSGS&#44; minimal change disease or idiopathic membranous nephropathy &#40;MN&#41;&#46; <span class="elsevierStyleBold">Methods&#58;</span> We measured circulating suPAR at diagnosis in 60 patients with nephrotic syndrome secondary to FSGS&#44; minimal change disease &#40;MCD&#41; and membranous nephropathy &#40;MN&#41;&#46; The correlations between suPAR levels and demographic&#44; clinical and biochemical variables were analysed&#46; The sensitivity and specificity of suPAR in distinguishing FSGS patients were analysed by ROC curves&#46; <span class="elsevierStyleBold">Results&#58;</span> After adjusting for age and renal function&#44; suPAR levels were significantly higher in patients with FSGS than in those with MCD &#40;<span class="elsevierStyleItalic">p</span>&#60;&#46;001&#41;&#44; but there were no differences between FSGS and MN &#40;<span class="elsevierStyleItalic">P</span>&#61;&#46;12&#41;&#46; A suPAR value &#8805;3452pg&#47;ml had a sensitivity of 73&#46;7&#37; and a specificity of 72&#46;5&#37;&#44; with an area under the curve &#40;AUC&#41; of 0&#46;782&#177;0&#46;124&#44; <span class="elsevierStyleItalic">p</span>&#61;&#46;001&#44; for identifying patients with FSGS&#46; After excluding patients with MN&#44; a value &#8805;3531pg&#47;ml had a specificity of 99&#46;93&#37; for distinguishing between MCD and FSGS&#46; <span class="elsevierStyleBold">Conclusions&#58;</span> suPAR values alone do not distinguish between the three types of glomerulopathy&#46; Nevertheless&#44; after excluding the diagnosis of MN&#44; a suPAR level &#62;3531pg&#47;ml could have a high specificity &#40;but a low sensitivity&#41; in the diagnosis of FSGS&#46;</p>"
      ]
    ]
    "multimedia" => array:6 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54357_en_t112256i.jpg"
            "Alto" => 909
            "Ancho" => 2152
            "Tamanyo" => 364798
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Clinical-demographic variables in the patient sample studied"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54358_en_t212256i_copy1.jpg"
            "Alto" => 372
            "Ancho" => 2175
            "Tamanyo" => 112356
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Variables associated with circulating levels of soluble urokinase-type plasminogen activator receptor&#46; ANOVA"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54359_en_f112256i.jpg"
            "Alto" => 822
            "Ancho" => 1006
            "Tamanyo" => 116428
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Levels of soluble urokinase-type plasminogen activator receptor by glomerular disease type"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig4"
        "etiqueta" => "Fig. 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54361_en_f212256i.jpg"
            "Alto" => 620
            "Ancho" => 2112
            "Tamanyo" => 172222
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Correlations between serum levels of soluble urokinase-type plasminogen activator receptor&#44; clinical and biochemical variables in the sample"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig5"
        "etiqueta" => "Fig. 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54362_en_f312256i.jpg"
            "Alto" => 1060
            "Ancho" => 1019
            "Tamanyo" => 126453
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Soluble urokinase-type plasminogen activator receptor values for identifying patients with idiopathic focal segmental glomerulosclerosis"
        ]
      ]
      5 => array:8 [
        "identificador" => "fig6"
        "etiqueta" => "Fig. 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12256_16025_54363_en_f412256i.jpg"
            "Alto" => 1070
            "Ancho" => 1001
            "Tamanyo" => 123484
          ]
        ]
        "descripcion" => array:1 [
          "en" => "ROC curve of soluble urokinase-type plasminogen activator receptor values to distinguish between focal segmental glomerulosclerosis and minimal change disease"
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003400000001/v0_201502091619/X2013251414053654/v0_201502091620/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35441"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003400000001/v0_201502091619/X2013251414053654/v0_201502091620/en/P1-E565-S4482-A12256-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414053654?idApp=UINPBA000064"
]
Article information
ISSN: 20132514
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 6 9 15
2024 October 34 27 61
2024 September 53 28 81
2024 August 52 60 112
2024 July 45 38 83
2024 June 50 40 90
2024 May 58 27 85
2024 April 36 40 76
2024 March 34 27 61
2024 February 31 39 70
2024 January 32 25 57
2023 December 30 37 67
2023 November 48 32 80
2023 October 35 47 82
2023 September 30 248 278
2023 August 45 17 62
2023 July 31 33 64
2023 June 27 24 51
2023 May 64 43 107
2023 April 34 19 53
2023 March 44 21 65
2023 February 26 21 47
2023 January 28 29 57
2022 December 56 53 109
2022 November 59 46 105
2022 October 62 47 109
2022 September 41 34 75
2022 August 43 37 80
2022 July 33 65 98
2022 June 38 53 91
2022 May 39 24 63
2022 April 27 52 79
2022 March 44 56 100
2022 February 36 47 83
2022 January 53 33 86
2021 December 30 41 71
2021 November 40 25 65
2021 October 44 51 95
2021 September 31 37 68
2021 August 55 33 88
2021 July 74 34 108
2021 June 44 29 73
2021 May 82 39 121
2021 April 112 80 192
2021 March 94 36 130
2021 February 69 27 96
2021 January 53 26 79
2020 December 59 17 76
2020 November 40 15 55
2020 October 23 15 38
2020 September 39 8 47
2020 August 40 16 56
2020 July 41 8 49
2020 June 22 13 35
2020 May 48 10 58
2020 April 49 17 66
2020 March 31 18 49
2020 February 49 26 75
2020 January 47 20 67
2019 December 54 19 73
2019 November 44 27 71
2019 October 38 14 52
2019 September 45 18 63
2019 August 30 15 45
2019 July 29 24 53
2019 June 45 26 71
2019 May 44 21 65
2019 April 92 39 131
2019 March 62 34 96
2019 February 39 19 58
2019 January 41 21 62
2018 December 132 50 182
2018 November 98 18 116
2018 October 91 15 106
2018 September 87 20 107
2018 August 68 22 90
2018 July 56 12 68
2018 June 69 17 86
2018 May 76 15 91
2018 April 80 17 97
2018 March 65 11 76
2018 February 81 18 99
2018 January 75 17 92
2017 December 101 8 109
2017 November 87 21 108
2017 October 56 9 65
2017 September 61 25 86
2017 August 71 22 93
2017 July 79 11 90
2017 June 82 21 103
2017 May 74 21 95
2017 April 74 21 95
2017 March 63 11 74
2017 February 53 15 68
2017 January 28 17 45
2016 December 82 7 89
2016 November 81 15 96
2016 October 174 15 189
2016 September 150 5 155
2016 August 244 13 257
2016 July 203 11 214
2016 June 173 0 173
2016 May 164 0 164
2016 April 148 0 148
2016 March 116 0 116
2016 February 141 0 141
2016 January 138 0 138
2015 December 150 0 150
2015 November 131 0 131
2015 October 119 0 119
2015 September 114 0 114
2015 August 116 0 116
2015 July 96 0 96
2015 June 47 0 47
2015 May 74 0 74
2015 April 8 0 8
Show all

Follow this link to access the full text of the article

Idiomas
Nefrología (English Edition)
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?